Trade NeuroBo Pharmaceuticals, Inc. - NRBO CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | - | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Neurobo Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 0.36-63.85 |
Average Volume (10 days) | 132.33K |
Average Volume (3 months) | 8.10M |
Market Cap | 17.60M |
P/E Ratio | -100.00K |
Shares Outstanding | 38.43M |
Revenue | N/A |
EPS | -4.23 |
Dividend (Yield %) | N/A |
Beta | 0.02 |
Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|
NeuroBo Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 13, 2023 | ||
Time (UTC) 21:00 | Country US
| Event Q3 2023 Neurobo Pharmaceuticals Inc Earnings Release Q3 2023 Neurobo Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 19.628 | 15.298 | 29.716 | 21.29 | 22.805 |
Selling/General/Admin. Expenses, Total | 8.64 | 8.752 | 7.846 | 2.701 | 8.493 |
Research & Development | 2.778 | 6.546 | 4.531 | 5.324 | 14.312 |
Unusual Expense (Income) | 8.21 | 0 | 17.339 | 13.265 | |
Operating Income | -19.628 | -15.298 | -29.716 | -21.29 | -22.805 |
Interest Income (Expense), Net Non-Operating | -2.191 | 0.014 | 0.039 | -0.022 | -0.654 |
Other, Net | 7.852 | 0 | -0.001 | 0 | -0.178 |
Net Income Before Taxes | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Net Income After Taxes | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Net Income Before Extra. Items | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Net Income | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Income Available to Common Incl. Extra. Items | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Diluted Net Income | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 |
Diluted Weighted Average Shares | 2.57362 | 0.77138 | 0.54052 | 0.17412 | 0.01841 |
Diluted EPS Excluding Extraordinary Items | -5.42698 | -19.8138 | -54.906 | -122.397 | -1284.23 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -2.23692 | -19.8138 | -22.8279 | -46.2148 | -1284.23 |
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 3.806 | 2.52 | 10.43 | 3.104 | 3.219 |
Selling/General/Admin. Expenses, Total | 1.442 | 1.883 | 1.915 | 2.533 | 2.237 |
Research & Development | 2.364 | 0.637 | 0.305 | 0.571 | 0.982 |
Operating Income | -3.806 | -2.52 | -10.43 | -3.104 | -3.219 |
Interest Income (Expense), Net Non-Operating | -2.191 | 0 | 0 | ||
Other, Net | 3.072 | -0.084 | 7.945 | -0.009 | -0.084 |
Net Income Before Taxes | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Net Income After Taxes | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Net Income Before Extra. Items | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Net Income | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Income Available to Common Excl. Extra. Items | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Income Available to Common Incl. Extra. Items | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Diluted Net Income | -0.734 | -2.604 | -4.676 | -3.113 | -3.303 |
Diluted Weighted Average Shares | 40.472 | 27.1767 | 7.62842 | 0.88869 | 0.88873 |
Diluted EPS Excluding Extraordinary Items | -0.01814 | -0.09582 | -0.61297 | -3.5029 | -3.71656 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.01814 | -0.09582 | 0.46327 | -3.5029 | -3.71656 |
Unusual Expense (Income) | 8.21 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 33.532 | 16.584 | 10.683 | 14.118 | 19.686 |
Cash and Short Term Investments | 33.364 | 16.387 | 10.089 | 13.908 | 18.954 |
Cash & Equivalents | 33.364 | 16.387 | 10.089 | 13.908 | 18.954 |
Prepaid Expenses | 0.168 | 0.197 | 0.546 | 0.153 | 0.715 |
Total Assets | 33.534 | 16.799 | 10.968 | 14.468 | 19.694 |
Other Long Term Assets, Total | 0.008 | ||||
Total Current Liabilities | 11.784 | 2.157 | 3.695 | 2.082 | 11.919 |
Accounts Payable | 0.708 | 0.83 | 2.575 | 0.638 | 2.044 |
Accrued Expenses | 0.28 | 1.327 | 1.12 | 1.444 | 0.438 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 10.796 | ||||
Total Liabilities | 11.784 | 2.202 | 3.765 | 2.176 | 11.92 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0.045 | 0.07 | 0.094 | 0.001 |
Total Equity | 21.75 | 14.597 | 7.203 | 12.292 | 7.774 |
Common Stock | 0.025 | 0.027 | 0.02 | 0.016 | 0.022 |
Additional Paid-In Capital | 117.52 | 96.394 | 73.713 | 49.13 | 91.863 |
Retained Earnings (Accumulated Deficit) | -95.795 | -81.828 | -66.544 | -36.866 | -84.111 |
Total Liabilities & Shareholders’ Equity | 33.534 | 16.799 | 10.968 | 14.468 | 19.694 |
Total Common Shares Outstanding | 25.436 | 0.88864 | 0.65564 | 0.51971 | 0.01902 |
Other Current Assets, Total | 0 | 0.048 | 0.057 | 0.017 | |
Current Port. of LT Debt/Capital Leases | 9.437 | ||||
Long Term Debt | 0 | 0 | |||
Property/Plant/Equipment, Total - Net | 0.002 | 0.215 | 0.285 | 0.35 | |
Property/Plant/Equipment, Total - Gross | 0.03 | 0.326 | 0.348 | 0.367 | |
Accumulated Depreciation, Total | -0.028 | -0.111 | -0.063 | -0.017 | |
Other Equity, Total | 0 | 0.004 | 0.014 | 0.012 | |
Preferred Stock - Non Redeemable, Net | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 31.483 | 33.532 | 7.554 | 10.077 | 13.264 |
Cash and Short Term Investments | 30.813 | 33.364 | 6.356 | 8.849 | 11.557 |
Cash & Equivalents | 30.813 | 33.364 | 6.356 | 8.849 | 11.557 |
Prepaid Expenses | 0.67 | 0.168 | 0.859 | 1.228 | 1.707 |
Other Current Assets, Total | 0.339 | ||||
Total Assets | 31.488 | 33.534 | 7.557 | 10.082 | 13.461 |
Property/Plant/Equipment, Total - Net | 0.005 | 0.002 | 0.003 | 0.005 | 0.197 |
Property/Plant/Equipment, Total - Gross | 0.034 | 0.03 | 0.03 | 0.03 | 0.32 |
Accumulated Depreciation, Total | -0.029 | -0.028 | -0.027 | -0.025 | -0.123 |
Total Current Liabilities | 10.98 | 11.784 | 1.619 | 1.249 | 1.496 |
Accounts Payable | 1.119 | 0.708 | 1.075 | 0.664 | 0.776 |
Accrued Expenses | 0.417 | 0.28 | 0.544 | 0.585 | 0.72 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10.98 | 11.784 | 1.619 | 1.249 | 1.533 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0 | 0.037 | |
Total Equity | 20.508 | 21.75 | 5.938 | 8.833 | 11.928 |
Common Stock | 0.027 | 0.025 | 0.001 | 0.027 | 0.027 |
Additional Paid-In Capital | 118.88 | 117.52 | 97.056 | 96.812 | 96.601 |
Retained Earnings (Accumulated Deficit) | -98.399 | -95.795 | -91.119 | -88.006 | -84.703 |
Other Equity, Total | 0 | 0 | 0 | 0.003 | |
Total Liabilities & Shareholders’ Equity | 31.488 | 33.534 | 7.557 | 10.082 | 13.461 |
Total Common Shares Outstanding | 27.1767 | 25.436 | 0.88869 | 0.88864 | 0.88864 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 9.444 | 10.796 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.967 | -15.284 | -29.678 | -21.312 | -15.529 |
Cash From Operating Activities | -11.712 | -15.134 | -10.764 | -7.039 | -14.451 |
Non-Cash Items | 3.403 | 0.686 | 18.059 | 13.512 | 1.856 |
Cash Taxes Paid | 0 | 0 | 0 | ||
Cash Interest Paid | 0 | 0.001 | 0 | ||
Changes in Working Capital | -1.168 | -0.584 | 0.809 | 0.744 | -0.778 |
Cash From Financing Activities | 28.681 | 22.026 | 6.858 | 24.167 | 17.246 |
Financing Cash Flow Items | -3.569 | -2.089 | -0.695 | -0.074 | -0.054 |
Issuance (Retirement) of Stock, Net | 32.25 | 24.115 | 7.553 | 24.241 | 16.8 |
Issuance (Retirement) of Debt, Net | 0 | 0.5 | |||
Net Change in Cash | 16.977 | 6.298 | -3.834 | 11.078 | 2.795 |
Cash From Operating Activities | 0.02 | 0.048 | 0.046 | 0.017 | 0 |
Cash From Investing Activities | 0.008 | -0.586 | 0.069 | -6.057 | -0.003 |
Capital Expenditures | 0 | -0.003 | -0.004 | -0.214 | -0.003 |
Other Investing Cash Flow Items, Total | 0.008 | -0.583 | 0.073 | -5.843 | 0 |
Foreign Exchange Effects | 0 | -0.008 | 0.003 | 0.007 | 0.003 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.604 | -13.967 | -9.291 | -6.178 | -2.875 |
Cash From Operating Activities | -2.547 | -11.712 | -9.905 | -7.546 | -4.829 |
Cash From Operating Activities | 0.001 | 0.02 | 0.019 | 0.017 | 0.012 |
Non-Cash Items | 0.01 | 3.403 | 0.719 | 0.501 | 0.213 |
Cash Taxes Paid | |||||
Cash Interest Paid | |||||
Changes in Working Capital | 0.046 | -1.168 | -1.352 | -1.886 | -2.179 |
Cash From Investing Activities | -0.004 | 0.008 | 0.008 | 0.008 | 0 |
Capital Expenditures | -0.004 | 0 | 0 | ||
Cash From Financing Activities | 0 | 28.681 | -0.134 | 0 | 0 |
Financing Cash Flow Items | 0 | -3.569 | -0.134 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 32.25 | 0 | 0 | 0 | |
Foreign Exchange Effects | 0 | 0 | 0 | 0 | -0.001 |
Net Change in Cash | -2.551 | 16.977 | -10.031 | -7.538 | -4.83 |
Other Investing Cash Flow Items, Total | 0.008 | 0.008 | 0.008 | 0 |
NeuroBo Pharmaceuticals, Inc. Company profile
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.Industry: | Bio Therapeutic Drugs |
200 Berkeley St.
Fl 19
BOSTON
MASSACHUSETTS 02116
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com